The Wisdom of Menopause
Page 90
64. Mann, S. J. (1999). Healing Hypertension: A Revolutionary New Approach (2). New York: John Wiley.
65. Ferketich, A. K., et al. (2000). Depression as an antecedent to heart disease among women and men in the NHANES I Study. Arch Intern Med, 160, 1261–1268.
66. Sinatra, S. (Aug. 26, 2010). Heart failure in women: a serious and insidious condition. Guest author on www.drnorthrup.com.
67. Jeppesen, J. (1997). Effects of low-fat high-carbohydrate diets on risk for ischemic heart disease in postmenopausal women. Am J Clin Nutr, 65 (4), 1027–1033.
68. Kearney, M. T., et al. (1997). William Heberden revisited: Postprandial angina—interval between food and exercise and meal composition are important determinants of time to onset of ischemia and maximal exercise tolerance. J Am Coll Cardiol, 29 (2), 302–307.
69. To read this book online, see www.seleneriverpress.com/media/pdf_docs/0_How_to_Prevent_Heart_Attacks_BEN_SANDLER_MD_1958.pdf.
70. Sieri, S., et al. (2010). Dietary glycemic load and index and risk of coronary heart disease in a large Italian cohort: The EPICOR study. Arch Intern Med, 170, 640–647.
71. Crapo, P. A., et al. (1976). Plasma glucose and insulin responses to orally administered simple and complex carbohydrates. Diabetes, 25 (9), 741–747; Crapo, P. A. (1977). Postprandial plasma-glucose and -insulin responses to different complex carbohydrates. Diabetes, 26 (12), 1178–1183.
72. Modan, M., et al. (1985). Hyperinsulinemia: A link between hypertension, obesity and glucose intolerance. J Clin Invest, 75, 809–817.
73. Ridker, P. M., et al. (2000). C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med, 342 (12), 836–843; Black, H. R. (1990). Coronary artery disease paradox: The role of hyperinsulinemia and insulin resistance and its implications for therapy. J Cardiovasc Pharmacol, 15 (suppl. 5), 26S–38S; Brindley, D. M., & Rolland, Y. (1989). Possible connections between stress, diabetes, obesity, hypertension, and altered lipoprotein metabolism that may result in arteriosclerosis. Clin Sci, 77 (5), 453–461; DeFronzo, R., & Ferrannini, E. (1991). Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care, 14 (3), 173–194; Eades, M., & Eades, M. D. (1996). Protein Power. New York: Bantam; Kazer, R. (1995). Insulin resistance, insulin-like growth factor I and breast cancer: A hypothesis. Int J Cancer, 62, 403–406; Lehninger, A. L. (1993). Principles of Biochemistry. New York: Worth; Jeppesen, J. (1997). Op. cit.
74. Tribble, D. L. (1999). AHA science advisory. Antioxidant consumption and risk of coronary heart disease: Emphasis on vitamin C, vitamin E, and betacarotene: A statement for health care professionals from the American Heart Association. Circulation, 99 (4), 591–595.
75. Anderson, J. W., et al. (1995). Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med, 333 (5), 276–282.
76. Nelson, G. J., & Chamberlain, J. G. (1995). The effects of dietary alphalinolenic acid on blood lipids and lipoproteins in humans. In Cunnane, S. C., & Thompson, L. U. (eds.). Flaxseed in Human Nutrition. Champaign, IL: AOCS Press; Nestel, P. J., Pomeroy, S. E., Sasahard, T., et al. (1997). Arterial compliance in obese subjects is improved with dietary plant n-3 fatty acid from flaxseed oil despite increased LDL oxidizability. Arterioscler Throm Vasc Biol, 17, 1163–1170.
77. Li, S. H., et al. (2010). Effect of oral isoflavone supplementation on vascular endothelial function in postmenopausal women: A meta-analysis of randomized placebo-controlled trials. Am J Clin Nutr, 91, 480–486.
78. Witteman, J. C., et al. (1994). Reduction of blood pressure with oral magnesium supplementation in women with mild to moderate hypertension. Am J Clin Nutr, 60 (1), 129–135.
79. Eisenberg, M. J. (1992). Magnesium deficiency and sudden death. Am Heart J, 124, 2, 544–549; Turlapaty, P. D., & Altura, B. M. (1980). Magnesium deficiency produces spasms in coronary arteries: Relationship to etiology of sudden death ischemic heart disease. Science, 208 (4440), 198–200; Altura, B. M. (1979). Sudden death ischemic heart disease and dietary magnesium intake: Is the target site coronary vascular smooth muscle? Med Hypotheses, 5, 8, 843–848.
80. Altura, B. M., et al. (1991). Cardiovascular risk factors and magensium: Relationships to atherosclerosis, ischemic heart disease, and hypertension. Magnes Trace Elem, 10, 182–192; Bostick, R. M. (1999). Relation of Ca+, vitamin D, and dairy food intake to ischemic heart disease mortality among postmenopausal women. Am J Epidemiol, 149 (2), 151–161; Morrison, H., et al. (1996). Serum folate and risk of fatal coronary heart disease. JAMA, 275 (24), 1893–1896; Stampfer, M. J., et al. (1993). Vitamin E consumption and the risk of coronary disease in women. N Engl J Med, 328, 1444–1449; Yochum, L., et al. (1999). Dietary flavonoid intake and risk of cardiovascular disease in postmenopausal women. Am J Epidemiol, 149 (10), 943–949; Kushi, L. H., et al. (1996). Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med, 334, 1156–1162.
81. Digiesi, V., et al. (1990). Effect of coenzyme Q10 on essential hypertension. Curr Ther Res, 47, 841–845.
82. Ghirlanda, G., et al. (1993). Evidence of plasma CoQ10-lowering effects by HMG-CoA reductase inhibitors: A double-blind, placebo-controlled study. J Clin Pharmacol, 33, 226–229.
83. Singh, R. B., et al. (1999). Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. J Human Hypertension, 13 (3), 203–208.
84. Yamagami, T., et al. (1977). Study of coenzyme Q10 in essential hypertension. In K. Folkers & Y. Yamamura (eds.), Biochemical and Clinical Aspects of Coenzyme Q10, vol. 1 (231–242). Amsterdam: Elsevier.
85. Singh, R. B., et al. (2003). Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction. Mol Cell Biochem, 246 (1–2), 75–82.
86. Sinatra, S. (1998). The Coenzyme Q10 Phenomenon. Los Angeles: Keats Publishing.
87. Howard, A. N., et al. (1996). Do hydroxycarotenoids prevent coronary heart disease? A comparison between Belfast and Toulouse. Int J Vitamin Nutr Res, 66, 113–118.
88. Stampfer, M. J., et al. (1993). Vitamin E consumption and the risk of coronary disease in women. N Engl J Med, 328 (20), 1444–1449.
89. Stephens, N. G., et al. (1996). Randomized controlled trial of vitamin E in patients with coronary disease. Cambridge Heart Antioxidant Study (CHAOS). Lancet, 347, 781–786.
90. Pocobelli, G., et al. (2009). Use of supplements of multivitamins, vitamin C, and vitamin E in relation to mortality. Am J Epidemiol, 170, 472–483.
91. Miller, E. R. (2005). Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med, 142 (1), 37–46.
92. Bostick, R. M., et al. (1993). Reduced risk of colon cancer with high intakes of vitamin E: The Iowa women’s health study. Cancer Res, 53 (18), 4230–4237.
93. Zandi, P. P. (2004). Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: The Cache County study. Arch Neurol, 61 (1), 82–88.
94. Lu, M. (2005). Prospective study of dietary fat and risk of cataract extraction among US women. Am J Epidemiol, 161 (10), 948–959.
95. Newaz, M. A., & Nawal, N. N. (1999). Effect of gamma-tocotrienol on blood pressure, lipid peroxidation and total antioxidant status in spontaneously hypertensive rats (SHR). Clin Exp Hyperens, 21 (8), 1297–1313; Qureshi, A. A., & Peterson, D. M. (2001). The combined effects of novel tocotrienols and lovastatin on lipid metabolism in chickens. Atherosclerosis, 156 (1), 39–47; Sen, C. K., Khanna, S., Roy, S., & Packer, L. (2000). Molecular basis of vitamin E action. Tocotrienol potently inhibits glutamate-induced pp60(c-Src) kinase activation and death of HT4 neuronal cells. J Biol Chem, 275 (17), 13049–13055; Theriault, A., et al. (1999). Tocotrienol: A review of its therapeutic potential. Clin Biochem, 32 (5), 309–319.
96. Janson, M. (1997). Drug free management of hypertension. Am J Nat Med, 4 (8), 14–17.
98. Anderson, J. L., et al. (2010). Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol, 106, 963–968.
99. Gaziano, J. M. (1994). Antioxidant vitamins and coronary artery disease risk. Am J Med, 97 (suppl.), 3S–18S, 3S–21S; Nenseter, M. S., Volden, V., Berg, T., et al. (1995). No effect of beta-carotene supplementation on the susceptibility of low-density lipoprotein to in vitro oxidation among hypercholesterolaemic postmenopausal women. Scan J Clin Lab Invest, 55, 477–485; Riemersma, R. A., et al. (1991). Risk of angina pectoris and plasma concentrations of vitamin A, E, C, and carotene. Lancet, 337 (8732), 1–5; Stampfer, M. J., Hennekens, C. H., Manson, J. E., et al. (1993). Vitamin E consumption and the risk of coronary disease in women. N Engl J Med, 328 (20), 1444–1449; Steinberg, E., et al. (1992). Antioxidants in the prevention of human atherosclerosis. Circulation, 85 (6), 2238–2343; Street, D. A., Comstock, G. W., Salkeld, R. M., Schuep, W., &Klag, M. J. (1994). Serum antioxidants and myocardial infarction. Are low levels of carotenoids and alpha-tocopherol risk factors for myo cardial infarction? Circulation, 90 (3), 1154–1161.
100. Rimm, E. B. (1998). Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA, 279, 359–364.
101. Zhang, L. H., et al. (2008). Niacin inhibits surface expression of ATP synthase beta chain in HepG2 cells: Implications for raising HDL. J Lipid Res, 49, 1195–1201.
102. Becker D. J., et al. (2009). Red yeast rice for dyslipidemia in statinintolerant patients: A randomized trial. Ann Intern Med, 150, 830–839, W147–149.
103. Heber, D., et al. (1999). Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr, 69, 231–236.
104. Lin, C. C., et al. (2005). Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia. Eur J Endocrinol, 153, 679–686.
105. Lu, Z., et al. (June 15, 2008). Chinese Coronary Secondary Prevention Study Group. Effect of Xuezhikang, an extract from red yeast rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol, 101, 1689–1693.
106. Becker, D. J., et al. (2008). Simvastatin vs. therapeutic lifestyle changes and supplements: Randomized primary prevention trial. Mayo Clin Proc, 83, 758–764.
107. Iso, H., et al. (2001). Intake of fish and omega-3 fatty acids and risk of stroke in women. JAMA, 285, 304–312.
108. Leaf, A., et al. (1988). Cardiovascular effect of n-3 fatty acids. N Engl J Med, 318 (9), 549–557; von Schaky, C., et al. (1999). The effect of dietary omega-3 fatty acids in coronary atherosclerosis: A randomized, doubleblind, placebo-controlled trial. Ann Intern Med, 130 (7), 554–562.
109. Vanschoonbeek, K., et al. (2007). Plasma triacylglycerol and coagulation factor concentrations predict the anticoagulant effect of dietary fish oil in overweight subjects. J Nutr, 137, 7–13; Schwellenbach, L. J., et al. (2006). The triglyceride-lowering effects of a modest dose of docosahexaenoic acid alone versus in combination with low dose eicosapentaenoic acid in patients with coronary artery disease and elevated triglycerides. J Am Coll Nutr, 25, 480–485; Moore, C. S., et al. (2006). Oily fish reduces plasma triacylglycerols: A primary prevention study in overweight men and women. Nutrition, 22, 1012–1024; Vanschoonbeek, K., et al. (2004). Variable hypocoagulant effect of fish oil intake in humans: Modulation of fibrinogen level and thrombin generation. Arterioscler Thromb Vasc Biol, 24, 1734–1740.
110. Hertog, M. G., et al. (1997). Antioxidant flavonols and coronary heart disease. Lancet, 349 (9053), 699.
111. Jain, A. K., et al. (1993). Can garlic reduce levels of serum lipids? A controlled clinical study. Am J Med, 94, 632–635; Kleijnen, J., et al. (1989). Garlic, onions, and cardiovascular risk factors: A review of the evidence from human experiments with emphasis on commercially available preparations. Br J Clin Pharmacol, 28, 535–544; Mader, F. H. (1990). Treatment of hyperlipidemia with garlic powder tablets. Arzneim-Forsch, 40, 1111–1116; McMahon, F. G., & Vargas, R. (1993). Can garlic lower blood pressure? A pilot study. Pharmacotherapy, 13 (4), 406–407.
112. Berger, J. (1998). Herbal Rituals (132–138). New York: St. Martin’s Press.
113. Anderson, J. W., Johnstone, B. M., & Cook-Newell, M. E. (1995). Op. cit.; Zhuo, X. G., Melby, M. K., & Watanabe, S. (2004). Soy isoflavone intake lowers serum LDL cholesterol: A meta-analysis of 8 randomized controlled trials in humans. J Nutr, 134 (9), 2395–2400.
114. Hall, W. L., et al. (2005). Soy-isoflavone–enriched foods and inflammatory biomarkers of cardiovascular disease risk in postmenopausal women: Interactions with genotype and equol production. Am J Clin Nutr, 82 (6), 1260–1268.
115. Desroches, S., et al. (2004). Soy protein favorably affects LDL size independently of isoflavones in hypercholesterolemic men and women. J Nutr, 134 (3), 574–579; Nagata, C., et al. (2003). Soy product intake is inversely associated with serum homocysteine level in premenopausal Japanese women. J Nutr, 133 (3), 797–800.
116. Anderson, J. J., et al. (1999). Health potential of soy isoflavones for menopausal women. Public Health Nutr, 2 (4), 489–504.
117. Jenkins, D. J., et al. (2002). Effects of high-and low-isoflavone soyfoods on blood lipids, oxidized LDL, homocysteine, and blood pressure in hyperlipidemic men and women. Am J Clin Nutr, 76 (2), 365–372.
118. Food & Drug Administration, U.S. Department of Health and Human Services (1999). FDA talk paper: FDA approves new health claim for soy protein and coronary heart disease (T99–48).
119. Anderson, J. W., & Hoie, L. H. (2005). Weight loss and lipid changes with low-energy diets: Comparator study of milk-based versus soy-based liquid meal replacement interventions. J Am Coll Nutr, 24 (3), 210–216.
120. Skrabal, F. (1981). Low sodium/high potassium diet for the prevention of hypertension: Probable mechanisms of action. Lancet, 2 (8252), 895–900.
121. Alpers, G. W., et al. (1999). Antiplatelet therapy: New foundations for optimal treatment decisions. Neurology, 53 (7, suppl. 4), 25S–31S; Antiplatelet Trialists’ Collaboration (1994). Collaborative overview of randomised trials of antiplatelet therapy—1: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ, 308, 81–106; DeAbago, F. J., et al. (1999). Association between SSRIs and upper GI bleeding. BMJ, 319, 1106–1109; Easton, J. D., et al. (1999). Antiplatelet therapy: Views from the experts. Neurology, 53 (7, suppl. 4), 32S–37S; Rong, Y., et al. (1994). Pycnogenol protects vascular endothelial cells from induced oxidant injury. Biotechnol Ther, 5 (3–4), 117–126.
122. Ridker, P. M., et al. (2005). A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med, 352 (13), 1293–1304.
123. Joshipura, K. J., et al. (1999). Fruit and vegetable intake in relation to risk of ischemic stroke. JAMA, 282 (13), 1233–1239.
124. Osganian, S. K., et al. (2003). Dietary carotenoids and risk of coronary artery disease in women. Am J Clin Nutr, 77 (6), 1390–1399.
125. Duffy, S. J., et al. (2001). Short-and long-term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. Circulation, 104 (2), 151–156.
126. Keli, S. O., et al. (1996). Dietary flavonoids, antioxidant vitamins, and incidence of stroke: The Zutphen study. Arch Intern Med, 156 (6), 637–642.
127. Quereshi, A. A., & Quereshi, N. (1993). Tocotrienols: Novel hypocholesterolemic agents with antioxidant properties. In Packer, L., & Fuchs, J. (eds.), Vitamin E in Health and Disease. New York: Marcel Dekker.
128. Oh, R. (2005). Practical applications of fish oil (omega-3 fatty acids) in primary care. J Am Board Fam Pract, 18 (1), 28–36; Mozaffarian, D., et al. (2005). Fish consumption and stroke risk in elderly individuals: The cardiovascular health study. Arch Intern Med, 165 (2), 200–2
06; Iso, H., et al. (2001). Intake of fish and omega-3 fatty acids and risk of stroke in women. JAMA, 285 (3), 304–312.
129. Hermsmeyer, R. K., et al. (2008). Cardiovascular effects of medroxy-progesterone acetate and progesterone: A case of mistaken identity? Nat Clin Pract Cardiovasc Med, 5, 387–395.
130. Nusselder, W. J., et al. (2009). Living healthier for longer: Comparative effects of three heart-healthy behaviors on life expectancy with and without cardiovascular disease. BMC Public Health, 9, 487.